CLBT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cellebrite DI Ltd (CLBT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and growth in ARR and subscription revenue make it a solid choice for long-term investment. Despite minor technical resistance, the overall outlook is positive, and the stock aligns with the user's investment goals.
The MACD is positively expanding with a histogram of 0.268, indicating bullish momentum. The RSI is at 73.023, which is in the neutral zone but leaning towards overbought territory. Moving averages are converging, suggesting consolidation. Key resistance levels are at 15.675, which the stock is approaching, and support levels are at 13.511. The stock has shown a strong regular market change of 7.27%, indicating positive momentum.
Cellebrite's AI-driven software is used by over 7,000 law enforcement agencies globally, supporting over 1.5 million investigations annually. The company has shown strong financial growth, with revenue up 18.13% YoY and ARR growing 21% YoY. Analysts maintain a Buy rating despite lowering price targets, citing solid execution and AI as a growth driver. The filing of the 2025 Annual Report reflects transparency and regulatory compliance.
Analysts have lowered price targets due to market contraction, and the stock's RSI is nearing overbought levels, which may indicate short-term resistance. The stock has a 30% chance of minor declines in the next week and month, based on candlestick pattern analysis.
In Q4 2025, Cellebrite reported revenue growth of 18.13% YoY to $128.82 million. Net income increased by 10.34% YoY to $21.26 million, and EPS remained stable at 0.08. Gross margin improved slightly to 84.71%, up 1.04% YoY. This demonstrates consistent financial performance and profitability.
Analysts from Needham, TD Cowen, and Lake Street maintain Buy ratings on CLBT, citing strong ARR growth, subscription revenue growth, and solid 2026 guidance. However, price targets have been lowered due to market contraction, with targets now ranging from $18 to $23.
